I-Mab - ADR

-0.47 (-3.81%)
Products, Regulatory

I-Mab Reports Latest Phase 2 Clinical Data Of Its Differentiated Cd73 Antibody Uliledlimab

Published: 05/26/2022 23:57 GMT
I-Mab - ADR (IMAB) - I-mab Reports Latest Phase 2 Clinical Data of Its Differentiated Cd73 Antibody Uliledlimab.
I-mab - Uliledlimab Appears Safe and Well-tolerated As a Monotherapy and a Combination Therapy With Toripalimab With No Dose Limiting Toxicity.
I-mab - Encouraging Efficacy Signals Were Observed in a Non-small Cell Lung Cancer (nsclc) Patient Cohort.
I-mab - Results Indicate Cd73 Expression Correlates With Clinical Response As a Potential Predictive Biomarker.
I-mab - Company Aims to Initiate Phase 3 Study in Nsclc in 2023.